Recent News

• 04.15.2025 - Tivic Health Extends its Worldwide License of TLR5 Agonist Entolimod to Include the Treatment of Neutropenia
• 04.10.2025 - Tivic Health Systems, Inc. Regains Compliance with NASDAQ Minimum Bid Price Listing Rule
• 03.21.2025 - Tivic Reports Year End 2024 Financial Results and Provides Overview of Strategy for Transformation and Growth
• 03.13.2025 - Tivic Health to Report 2024 Year-End Financial Results on March 21st Via Conference Call and Webcast
• 03.06.2025 - Tivic Health and Feinstein Institute Present New Data Showing Personalized Vagus Nerve Stimulation Method Optimizes Impact on Autonomic Nervous System
• 03.05.2025 - Tivic Health Systems, Inc. Announces Reverse Stock Split
• 03.03.2025 - Tivic Health Files Patent For Optimized Electrical Stimulation of the Vagus Nerve
• 02.24.2025 - Tivic Health Names Biotech Industry Veteran Michael K. Handley to Executive Leadership Team

Recent Filings

• 04.14.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 04.14.2025 - 8-K Current report
• 04.10.2025 - 8-K Current report
• 04.10.2025 - EX-99.1 EX-99.1
• 04.03.2025 - 8-K Current report
• 03.21.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.21.2025 - 8-K Current report
• 03.21.2025 - EX-99.1 EX-99.1
• 03.06.2025 - 8-K Current report
• 03.06.2025 - EX-99.1 EX-99.1